ALK and neuroblastoma: In addition, we found druggable mutations in several other genes, including BRCA1, ATM, HRAS, MET, ERBB2, and STK11. Several targeted agents, including ALK inhibitors, are in clinical trials for treatment of neuroblastoma [15].